Avoiding post-partum MS worsening

17th November 2014

French study supports the idea of avoiding delays after pregnancy before starting natalizumab therapy

Trigeminal neuralgia and fampridine: further contraindication

17th November 2014

Fampridine must be used with caution in people with a history of MS-related trigeminal neuralgia

New treatment for fatigue

17th November 2014

Researchers find that Alfacalcidol is a safe and effective treatment for fatigue

Phase one of European Register for MS completed

10th November 2014

The register aims to address the recognised lack of relevant MS data at European level

Treat Me Right campaign changes UK guidelines

6th November 2014

The UK MS Society’s campaign calls for the right treatment at the right time

Middle East volunteers trained in MS counselling

6th November 2014

Volunteers from MS organisations in Lebanon, Egypt and Jordan took part in a three-day training course

2014 McDonald Fellowships announced

6th November 2014

This year’s McDonald Fellowships went to researchers from Bangladesh, Hungary, Iran and Yemen

More Du Pré Grants for 2014 announced

6th November 2014

The second wave of 2014 grants includes scientists from Iran, Italy, Romania and Russia

New type of interferon has fewer side effects

28th October 2014

Pegylated interferon lasts longer, so needs to be taken less often, with fewer side effects

Pros and cons of alemtuzumab

28th October 2014

Alemtuzumab has been approved in Europe, Canada, Australia, and Latin America

Better test for risk of PML infection in Natalizumab patients

28th October 2014

The new test measures the risk of PML infection in people being treated with Natalizumab

New markers to stop inflammation in multiple sclerosis

23rd October 2014

An imbalance in the production of two molecules may play a role in MS inflammation